• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb

Bristol-Myers Squibb Company BMY

Last Price$73.00Day Change (%)1.91%
Open Price$72.12Day Change ($)1.37
Day Range71.96–73.1752-Week Range51.82–75.12

As of Wed 6/29/2016 6:32:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Bristol-Myers Squibb's bladder cancer treatment granted breakthrough therapy designation

    Bristol-Myers Squibb's bladder cancer treatment granted breakthrough therapy designation

  2. $39.4 Billion Biomarkers Report: Technologies and Global Markets to 2020 - Research and Markets

    $39.4 Billion Biomarkers Report: Technologies and Global Markets to 2020 - Research and Markets

  3. Combination Drug Therapies for Cancer Show Promise at Higher Potential Cost

    Combination Drug Therapies for Cancer Show Promise at Higher Potential Cost

  4. Combination Drug Therapies for Cancer Show Promise at Higher Potential Cost

    Combination Drug Therapies for Cancer Show Promise at Higher Potential Cost

  5. Global Small-Cell Lung Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: 4SC, Amgen, Johnson & Johnson - Research and Markets

    Global Small-Cell Lung Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: 4SC, Amgen, Johnson & Johnson - Research and Markets

  6. Global Autoinjectors Market Report 2016-2026 - Analysis, Technologies & Forecasts - Key Vendors: 3P Limited, Bayer Healthcare, Nuron Biotech - Research and Markets

    Global Autoinjectors Market Report 2016-2026 - Analysis, Technologies & Forecasts - Key Vendors: 3P Limited, Bayer Healthcare, Nuron Biotech - Research and Markets

  7. First Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (ipilimumab) Demonstrates Encouraging Clinical Activity in MSI-High Metastatic ...

    First Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (ipilimumab) Demonstrates Encouraging Clinical Activity in MSI-High Metastatic Colorectal Cancer

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.